Topic: childhood vaccines
If marketing is a persuasion business, why can’t a room full of marketing experts figure out how to change skeptics’ minds about vaccines?
Instead of launching their new combination pediatric shot now, Sanofi and Merck will spend this year building up supplies for a 2020 rollout.
Merck's RotaTeq won China approval in April and a launch is underway, but meanwhile, the company is reducing its shipments to low-income countries.
GlaxoSmithKline's moms against meningitis B are back on the air in TV ads promoting its Bexsero vaccine for back-to-college.
Sanofi Pasteur is urging parents to make sure teens get a second meningococcal booster vaccine in a new ad campaign timed for back-to-school.
Gavi's vaccine initiative will have saved 20 million lives and $350 billion in healthcare costs by 2020, a recent study found.
If Hilleman Labs is successful in scouting for a rotavirus vaccine partnership, India might see a new force added to its efforts to fight child and infant mortality caused by the deadly virus.
Right now, GlaxoSmithKline’s meningitis B vaccine, Bexsero, doesn’t have the key “universal use” endorsement the company wants from the CDC. So it’s spreading the word on its own.
Shortages of vaccines at clinics in China have predictably followed a move to eliminate middlemen from the sales chain.
Good news for GlaxoSmithKline, and those U.K. parents wanting to get their hands on its meningitis B vaccine, Bexsero: The wait is over.